Logo for LIDDS

LIDDS Investor Relations Material

Latest events

Logo for LIDDS

Q2 2024

28 Aug, 2024
Logo for LIDDS

Q1 2024

30 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from LIDDS

Access all reports
LIDDS AB is a Swedish pharmaceutical company that focuses on drug delivery technologies, particularly for cancer treatment. Its proprietary technology, NanoZolid, enables localized and controlled release of drugs for up to six months, reducing systemic side effects. LIDDS leverages this platform to develop its own oncology-focused pipeline, which includes candidates such as Nanodotax (a NanoZolid-formulated chemotherapy) and Nanoimod (a TLR9 agonist for cancer immunotherapy). The company's strategy also involves partnering with other pharmaceutical firms to enhance drug efficacy and safety using its drug delivery technology. LIDDS is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.